D-0309-2021 Class III Terminated
FDA drug recall D-0309-2021 was initiated by Teva Pharmaceuticals USA on Mar 4, 2021 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing. The recall status is terminated (terminated May 19, 2022). Affected quantity: 1,416 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 24, 2021
- Initiation Date
- Mar 4, 2021
- Termination Date
- May 19, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,416 vials
Product description
Romidepsin Injecton, 27.5 mg/5.5 mL (5 mg/mL) Rx Only, 5.5 ml vial, Teva Pharmaceuticals USA, Inc. NDC 0703-4004-01
Reason for recall
Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing.
Distribution pattern
Distributed Nationwide in the USA.
Code information
Lot # 31328184C, exp. date 11/2021 Lot # 31327686C, exp. date 08/2021 Lot # 31327685C, exp. date 08/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0309-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026